Vita Care

VitaCare Biotechnology is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the development of innovative biologics for oncology and immunology. The company's lead program, VCB-001, is a bifunctional fusion protein designed to simultaneously inhibit the PD-L1 and TGF-beta pathways, aiming to reverse immune suppression in the tumor microenvironment. VitaCare leverages a proprietary protein engineering platform to create a pipeline of next-generation immunotherapies, including bispecific antibodies and fusion proteins. With a focus on addressing unmet needs in solid tumors, the company conducts clinical trials in both China and the United States. VitaCare is backed by prominent life science investors, including 6 Dimensions Capital and Boyu Capital.